Y Intercept Hong Kong Ltd Makes New $1.81 Million Investment in Oruka Therapeutics, Inc. $ORKA

Y Intercept Hong Kong Ltd bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,912 shares of the company’s stock, valued at approximately $1,811,000.

A number of other hedge funds also recently modified their holdings of ORKA. Viking Global Investors LP acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $51,280,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at approximately $51,840,000. Remedium Capital Partners LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter worth $47,054,000. Avoro Capital Advisors LLC bought a new stake in shares of Oruka Therapeutics during the third quarter worth $25,640,000. Finally, Deep Track Capital LP raised its holdings in shares of Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ORKA. UBS Group boosted their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Weiss Ratings cut Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Guggenheim set a $200.00 price target on Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. BTIG Research restated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Thursday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 23rd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

Insiders Place Their Bets

In other news, Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares in the company, valued at approximately $2,716,271.73. The trade was a 24.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $80.95, for a total value of $128,467.65. Following the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,239,506.40. This represents a 9.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 185,407 shares of company stock valued at $11,636,307. Corporate insiders own 23.49% of the company’s stock.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $88.27 on Friday. The firm’s 50-day moving average is $70.17 and its 200-day moving average is $51.11. The stock has a market cap of $5.32 billion, a price-to-earnings ratio of -45.50 and a beta of -0.35. Oruka Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $97.78.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. Sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.